Journal
NATURE REVIEWS CANCER
Volume 17, Issue 8, Pages 475-488Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc.2017.42
Keywords
-
Categories
Funding
- UK National Health Service
- British Lung Foundation [VPDCF17-17] Funding Source: researchfish
- Cancer Research UK [15569, 21400] Funding Source: researchfish
Ask authors/readers for more resources
Malignant mesothelioma is a universally lethal cancer that is increasing in incidence worldwide. There is a dearth of effective therapies, with only one treatment (pemetrexed and cisplatin combination chemotherapy) approved in the past 13 years. However, the past 5 years have witnessed an exponential growth in our understanding of mesothelioma pathobiology, which is set to revolutionize therapeutic strategies. From a genomic standpoint, mesothelioma is characterized by a preponderance of tumour suppressor alterations, for which novel therapies are currently in development. Other promising antitumour agents include inhibitors against angiogenesis, mesothelin and immune checkpoints, which are at various phases of clinical trial testing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available